vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a research report issued on Wednesday, Benzinga reports. They presently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s price objective suggests a potential upside of 98.71% from the company’s previous close.
Other research analysts have also issued research reports about the company. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. HC Wainwright dropped their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Rodman & Renshaw began coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, vTv Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.
vTv Therapeutics Price Performance
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). Research analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.
About vTv Therapeutics
vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.
vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.
See Also
- Five stocks we like better than vTv Therapeutics
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
